Today: 22 November 2025
Subscribe
Browse Category

COVID-19 News 29 August 2025 - 14 November 2025

Invivyd (IVVD) Rockets Over 50% Pre‑Market on November 14, 2025 as Traders Rush Into COVID Antibody Play

Invivyd (IVVD) Rockets Over 50% Pre‑Market on November 14, 2025 as Traders Rush Into COVID Antibody Play

Invivyd, Inc. (NASDAQ: IVVD) is back in the spotlight this Friday, November 14, 2025, with its stock exploding higher in pre‑market trading on the back of building momentum around its COVID‑19 antibody franchise and recent earnings. By early morning, IVVD was one of the most actively watched biotech names on Wall Street. Invivyd stock today: IVVD among top pre‑market gainers Multiple market data sources show Invivyd staging a huge move before the opening bell: In short, Invivyd stock is up roughly 40–60% in Friday’s pre‑market session, depending on the venue and timestamp, after closing at $1.77 on November 13. Notably,
14 November 2025
 ·  ·  ·  ·  · 
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. (NASDAQ: MRNA) posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0 billion, cut operating‑expense guidance, and raised its year‑end cash outlook. Shares popped in pre‑market trading before wobbling intraday. SEC+1 What happened Moderna’s Q3 print outpaced expectations on both the top and bottom lines, led by stronger‑than‑modeled sales of its updated COVID‑19 shot (marketed this season as mNEXSPIKE/Spikevax 2025–26). Management simultaneously tightened the full‑year revenue band and lowered operating‑expense plans, signaling
6 November 2025
 ·  ·  ·  ·  · 
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once
16 October 2025
 ·  ·  ·  ·  · 
‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

What is the “Stratus” COVID variant? “Stratus” is the colloquial name for XFG, a recombinant Omicron descendant (from LF.7 and LP.8.1.2). WHO added XFG to its monitoring list in late June and, based on available evidence, concluded the “additional public‑health risk … is low.” WHO’s lab summary notes spike‑protein changes (e.g., at positions 478 and 487) that can modestly increase immune escape compared with earlier JN.1‑family strains. World Health Organization Globally, XFG gained speed over the summer. WHO’s dashboard reports XFG was ~67% of submitted sequences in the week ending 31 Aug 2025; the runner‑up, NB.1.8.1 (“Nimbus”), accounted for ~21%.
28 September 2025
 ·  ·  ·  · 
COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

Drug Approvals & Clinical Trial Results Updated COVID Boosters Get Narrow Nod: The U.S. FDA approved new fall COVID-19 booster shots from Pfizer/BioNTech and Moderna on August 27 – but with strict eligibility limits. Only adults 65+ and younger people with certain medical conditions are cleared for the updated vaccines, and emergency use authorizations for routine use in healthy children were removed realeconomy.rsmus.com. Health experts immediately sounded alarms: the Infectious Diseases Society of America blasted the “narrowed” booster rollout as contrary to scientific guidance and a risk to lives cidrap.umn.edu. They warn these restrictions could hinder access, especially for children,
29 August 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Go toTop